Vaxart Q3 Earnings Call Highlights
Vaxart, Inc. (VXRT) Q3 2026 Earnings Call Transcript
Vaxart Inc (VXRT) (Q3 2026) Earnings Call Highlights: Cash Runway Into Q2 2027, COVID-19 ...
Vaxart Provides Business Update and Reports Third Quarter 2026 Financial Results
Vaxart Q3 EPS $(0.07) Down From $(0.04) YoY, Sales $10.620M Down From $72.413M YoY
Vaxart to Host Stockholder Fireside Chat on November 6 at 4:30 p.m. ET
Vaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of Directors
Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model
Vaxart Announces Publication Of Preclinical Study Results Evaluating Its Oral Mucosal Vaccine Platform Against Highly Pathogenic Avian Influenza H5N1; Candidate VXA-H5-02 Induced Robust Cross-Neutralizing Antibodies
Vaxart, Inc. (VXRT) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Vaxart, Inc. (VXRT) Q2 2026 Stockholder Fireside Chat Call Transcript
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Inc (VXRT) (Q2 2026) Earnings Call Highlights: Oral COVID Vaccine Shows Promise, Cash ...
Vaxart Q2 Earnings Call Highlights
Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript
Vaxart, Inc. Q2 2026 Earnings Call Summary
Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.